These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 29545131)

  • 1. [Utilization of alfacalcidol and active vitamin D analogs in chronic kidney disease].
    Ureña-Torres PA; Cozzolino M; Bover J
    Nephrol Ther; 2018 Jun; 14(4):189-200. PubMed ID: 29545131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which vitamin D in CKD-MBD? The time of burning questions.
    Galassi A; Bellasi A; Auricchio S; Papagni S; Cozzolino M
    Biomed Res Int; 2013; 2013():864012. PubMed ID: 23991423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
    Bernardor J; De Mul A; Bacchetta J; Schmitt CP
    Curr Osteoporos Rep; 2023 Apr; 21(2):193-204. PubMed ID: 36848027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.
    Brancaccio D; Bommer J; Coyne D
    Drugs; 2007; 67(14):1981-98. PubMed ID: 17883283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Paricalcitol - a selective vitamin D receptor activator for secondary hyperparathyroidism in patients with chronic kidney disease].
    Matuszkiewicz-Rowińska J; Żebrowski P
    Wiad Lek; 2016; 69(5):756-759. PubMed ID: 28033603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease.
    Bover J; Egido J; Fernández-Giráldez E; Praga M; Solozábal-Campos C; Torregrosa JV; Martínez-Castelao A
    Nefrologia; 2015; 35(1):28-41. PubMed ID: 25611831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current treatment options for secondary hyperparathyroidism in patients with stage 3 to 4 chronic kidney disease and vitamin D deficiency.
    Galassi A; Ciceri P; Porata G; Iatrino R; Boni Brivio G; Fasulo E; Magagnoli L; Stucchi A; Frittoli M; Cara A; Cozzolino M
    Expert Opin Drug Saf; 2021 Nov; 20(11):1333-1349. PubMed ID: 33993809
    [No Abstract]   [Full Text] [Related]  

  • 8. The uses and abuses of Vitamin D compounds in chronic kidney disease-mineral bone disease (CKD-MBD).
    Goldsmith DJ; Massy ZA; Brandenburg V
    Semin Nephrol; 2014 Nov; 34(6):660-8. PubMed ID: 25498384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do the benefits of using calcitriol and other vitamin D receptor activators in patients with chronic kidney disease outweigh the harms?
    Toussaint ND; Damasiewicz MJ
    Nephrology (Carlton); 2017 Mar; 22 Suppl 2():51-56. PubMed ID: 28429545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised clinical study of alfacalcidol and paricalcitol.
    Hansen D
    Dan Med J; 2012 Feb; 59(2):B4400. PubMed ID: 22293059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphophonates in CKD patients with low bone mineral density.
    Liu WC; Yen JF; Lang CL; Yan MT; Lu KC
    ScientificWorldJournal; 2013; 2013():837573. PubMed ID: 24501586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
    Bover J; Ureña-Torres P; Lloret MJ; Ruiz C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
    Expert Opin Pharmacother; 2016 Jul; 17(10):1363-73. PubMed ID: 27156578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Failure of Active Vitamin D Therapy in Chronic Kidney Disease: Predictive Factors.
    Cozzolino M; Covic A; Martinez-Placencia B; Xynos K
    Am J Nephrol; 2015; 42(3):228-36. PubMed ID: 26439891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
    Cozzolino M; Brancaccio D
    Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Calcimimetics, phosphate binders, vitamin D and its analogues for treating secondary hyperparathyroidism in chronic kidney disease: guideline from the Italian Society of Nephrology].
    Mazzaferro S; Cozzolino M; Marangella M; Strippoli GF; Messa P;
    G Ital Nefrol; 2007; 24 Suppl 37():S107-24. PubMed ID: 17347960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
    Moe S; Wazny LD; Martin JE
    Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.
    Bover J; Bailone L; López-Báez V; Benito S; Ciceri P; Galassi A; Cozzolino M
    J Nephrol; 2017 Oct; 30(5):677-687. PubMed ID: 28432640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation.
    Pimentel A; Ureña-Torres P; Zillikens MC; Bover J; Cohen-Solal M
    Kidney Int; 2017 Dec; 92(6):1343-1355. PubMed ID: 28964571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Update on recent progress in vitamin D research. The role of vitamin D in management of CKD-MBD.].
    Hamano N; Fukagawa M
    Clin Calcium; 2017; 27(11):1609-1614. PubMed ID: 29074834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of paricalcitol in patients with chronic kidney disease.
    Dyer CA
    Expert Opin Drug Saf; 2013 Sep; 12(5):717-28. PubMed ID: 23621417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.